pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 2·1 min read
save

Updated: Allen Institute launches $400M effort to turn brain atlas lessons into medicines

A Seattle-based nonprofit known for basic brain research is launching a $400 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including Alzheimer's. It's a major new direction for the Allen Institute ...

Jun 2, 2026·read at Endpoints ↗

Allen Institute Brain Health Accelerator leader Ed Lein (L) and scientist Aaron Garcia examine a section of human brain. Photo credit: Erik Dinnel / Allen Institute June 2, 2026 05:00 AM EDT FinancingR&D Allen In­sti­tute launch­es $200M ef­fort to turn brain at­las lessons in­to med­i­cines Ryan Cross Senior Science Correspondent A Seat­tle-based non­prof­it known for ba­sic brain re­search is launch­ing a $200 mil­lion ini­tia­tive to trans­late its knowl­edge in­to drug de­vel­op­ment for neu­rode­gen­er­a­tive dis­eases, in­clud­ing … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
110 words · retrieved Jun 2
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
HER2

related stories

  • May 7Angelini fortifies neurology portfolio with $4.1B buyout of CatalystEndpoints
  • May 6Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinomaonclive
  • May 6Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Canceronclive
  • May 6Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLConclive
  • May 6Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myelomaonclive